Tanimoto [44] and Oberst [45] found that compared with early ovarian cancer, ST14 expression is weaker in clinical specimens of advanced ovarian cancer, and ST14-positive patients showed a longer survival time. Here, ST14 is linked to ovarian carcinoma.